Esperion Therapeutics Stock Forecast, Price & News

-1.19 (-5.08 %)
(As of 06/23/2021 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume18,504 shs
Average Volume744,055 shs
Market Capitalization$626.71 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Esperion Therapeutics logo

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.17 out of 5 stars

Medical Sector

29th out of 2,105 stocks

Pharmaceutical Preparations Industry

14th out of 832 stocks

Analyst Opinion: 4.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

Is Esperion Therapeutics a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 2 sell ratings, 5 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Esperion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View analyst ratings for Esperion Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Esperion Therapeutics?

Wall Street analysts have given Esperion Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Esperion Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Esperion Therapeutics

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its earnings results on Tuesday, May, 4th. The biopharmaceutical company reported ($3.50) EPS for the quarter, missing analysts' consensus estimates of ($2.08) by $1.42. The biopharmaceutical company earned $8 million during the quarter, compared to analyst estimates of $34.28 million. Esperion Therapeutics had a negative net margin of 66.86% and a negative trailing twelve-month return on equity of 629.88%. Esperion Therapeutics's revenue was up 344.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($2.84) earnings per share.
View Esperion Therapeutics' earnings history

How has Esperion Therapeutics' stock price been impacted by COVID-19?

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ESPR stock has decreased by 48.7% and is now trading at $22.04.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ESPR?

10 Wall Street analysts have issued 12-month price targets for Esperion Therapeutics' shares. Their forecasts range from $20.00 to $134.00. On average, they anticipate Esperion Therapeutics' share price to reach $49.27 in the next year. This suggests a possible upside of 123.6% from the stock's current price.
View analysts' price targets for Esperion Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the following people:
  • Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 60, Pay $986.92k)
  • Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 39, Pay $529.75k)
  • Mr. Sheldon L. Koenig, Chief Operating Officer (Age 55, Pay $507.64k)
  • Ms. Ashley Hall, Chief Devel. Officer (Age 49, Pay $889.75k)
  • Dr. Kenneth J. Fiorelli, Chief Technical Operations Officer
  • Mr. Benjamin Church, Head of Corp. Communications & Investor Relations
  • Mr. Keith F. Lenden, VP of Corp. Devel. & Strategy (Age 48)
  • Renee Marotta, Head of Marketing
  • Ms. April Seiler, Sr. Director of Project Management
  • Roberta Peterson, Sr. Director of National Accounts

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

Who are some of Esperion Therapeutics' key competitors?

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include (ALDW) (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), The Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (14.61%), Bellevue Group AG (14.15%), BlackRock Inc. (7.61%), Platinum Investment Management Ltd. (5.68%), Point72 Asset Management L.P. (2.30%) and Pentwater Capital Management LP (2.16%). Company insiders that own Esperion Therapeutics stock include Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics

Which institutional investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Nomura Holdings Inc., Endurant Capital Management LP, Morgan Stanley, Goldman Sachs Group Inc., Pinnacle Associates Ltd., Hamilton Lane Advisors LLC, and DCF Advisers LLC.
View insider buying and selling activity for Esperion Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Esperion Therapeutics stock?

ESPR stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Citigroup Inc., Wasatch Advisors Inc., Pentwater Capital Management LP, Nuveen Asset Management LLC, BlackRock Inc., Rafferty Asset Management LLC, and GAM Holding AG. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben.
View insider buying and selling activity for Esperion Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $22.04.

How much money does Esperion Therapeutics make?

Esperion Therapeutics has a market capitalization of $621.35 million and generates $227.55 million in revenue each year. The biopharmaceutical company earns $-143,550,000.00 in net income (profit) each year or ($5.23) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

Esperion Therapeutics employs 479 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is

Where are Esperion Therapeutics' headquarters?

Esperion Therapeutics is headquartered at 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.